A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer
therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been
shown to be particularly active against HDAC8. The objectives of this study are to determine
the safety profile of NBM-BMX, including identification of dose limiting toxicity (DLT) and
maximum tolerated dose (MTD), and to determine the Recommended Phase 2 Dose (RP2D).